Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: How early cancer screening could save Canada nearly half a billion dollars over patients' lifetimes

2.

Dissociative identity disorder: method or fact?

3.

Risk-Benefit Analysis of CAR-T Therapies for Myeloma is Muddy by Early Death Risk.

4.

Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC

5.

Belzutifan for Advanced Renal Cell Carcinoma is approved by the FDA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot